Literature DB >> 28488383

PAX6 allelic heterogeneity in Mexican congenital aniridia patients: expanding the mutational spectrum with seven novel pathogenic variants.

Sofía Pérez-Solórzano1, Oscar F Chacón-Camacho1, Mirena C Astiazarán1, Gerardo Ledesma-Gil2, Juan Carlos Zenteno1,3.   

Abstract

IMPORTANCE: The importance of the study was to describe the clinical characteristics and mutational analysis of Mexican patients with aniridia.
BACKGROUND: Aniridia is a panocular hereditary eye disease caused by mutations in the PAX6 transcription factor. Mutation detection rate is highly variable ranging from 30% to 90% in different populations. Very few studies have been published about the PAX6 mutational analysis in aniridia patients from Mexico. In order to establish a more representative PAX6 mutational frequency in the country, a cohort of 22 Mexican unrelated aniridia probands were analysed in this study.
DESIGN: Case series. PARTICIPANTS: A total of 22 Mexican probands with bilateral isolated aniridia and their available relatives were included.
METHODS: Sanger sequencing was used for the mutational analysis of all coding exons and flanking intronic regions of PAX6. MAIN OUTCOME MEASURES: Clinical characteristics and results of PAX6 mutational analysis in probands with aniridia and available family members.
RESULTS: Molecular analysis of PAX6 in 22 index cases with aniridia allowed the identification of a total of 16 different mutations. Seven of these pathogenic variants are novel, including c.183C>G, p.(Y61*); c.718delC, p.(R240Efs*3); c.1149_1152delTCAG, p.(P385Wfs*139); c.257_266delAAATAGCCCA, p.(K86Sfs*35); c.836_843dupGCAACACA p.(P282Afs*86); c.1032+2_1032+3insT; and c.141+2T>A. Inter and intrafamilial phenotypic heterogeneity was found. CONCLUSIONS AND RELEVANCE: The mutational diagnostic rate in this series was 77%, which is comparable with reports from other populations. Importantly, no founder mutations were identified in this case series. Our results add 7 novel PAX6 pathogenic variants to the aniridia-related mutational spectrum and reveal considerable PAX6 allelic heterogeneity in this population.
© 2017 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  DNA mutational analysis; aniridia; haploinsufficiency; hereditary eye diseases

Mesh:

Substances:

Year:  2017        PMID: 28488383     DOI: 10.1111/ceo.12982

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  3 in total

1.  Functional reassessment of PAX6 single nucleotide variants by in vitro splicing assay.

Authors:  Alexandra Yu Filatova; Tatiana A Vasilyeva; Andrey V Marakhonov; Anna A Voskresenskaya; Rena A Zinchenko; Mikhail Yu Skoblov
Journal:  Eur J Hum Genet       Date:  2018-10-12       Impact factor: 4.246

2.  Molecular analysis of Cypriot families with aniridia reveals a novel PAX6 mutation.

Authors:  Andreas Syrimis; Nayia Nicolaou; Angelos Alexandrou; Ioannis Papaevripidou; Michael Nicolaou; Eleni Loukianou; Carolina Sismani; Stavros Malas; Violetta Christophidou-Anastasiadou; George A Tanteles
Journal:  Mol Med Rep       Date:  2018-06-05       Impact factor: 2.952

3.  Two Paired Box 6 mutations identified in Chinese patients with classic congenital aniridia and cataract.

Authors:  Ying Lin; Hongbin Gao; Yi Zhu; Chuan Chen; Tao Li; Bingqian Liu; Cancan Lyu; Ying Huang; Haichun Li; Qingxiu Wu; Chenjin Jin; Xiaoling Liang; Xinhua Huang; Lin Lu
Journal:  Mol Med Rep       Date:  2018-09-10       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.